Waterkamp, Daniel
Genentech
2 papers on CoChat
Most cited papers
- Verified
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 2,756
- Verified
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Segal, N. H., Melero, I., Moreno, V., Steeghs, N., Marabelle, A., Rohrberg, K., Rodriguez-Ruiz, M. E., Eder, J. P., Eng, C., Manji, G. A., et al. (2024) · Nature Communications
Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research
Cited by 80
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free